Navigation Links
Verenium Corporation To Announce Second Quarter 2013 Financial Results
Date:7/25/2013

SAN DIEGO, July 25, 2013 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that it will release second quarter 2013 financial results on Wednesday, August 7, 2013 after market close. In conjunction with the release, the Company will host a conference call with live webcast on Wednesday, August 7, 2013 at 5:00 p.m. ET.

(Logo:  http://photos.prnewswire.com/prnh/20120924/MM79973LOGO)

The call may be accessed by dialing (877) 755-7422 (domestic) or (678) 894-3067 (international) five minutes prior to start time and providing the passcode 19911712.  A link to the live webcast may be accessed by visiting the "Investors" section of the Company's website at http://ir.verenium.com/.  A replay of the event will be available on the Company's website approximately two hours after the call and will be archived for 30 days.

About Verenium
Verenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes.  Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets.  Read more at www.verenium.com.

Forward Looking Statements
Statements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty.  These include, but are not limited to, statements related to Verenium's estimated revenues, operating loss and capital expenditures for the year ended December 31, 2012, unrestricted cash balance as of December 31, 2012, near-term opportunities and long-term growth prospects, the impact of Verenium's restatement of certain of its historical financial statements on its consolidated balance sheets and consolidated statement of operations for the relevant periods and its cash position, and Verenium's San Diego facility and the related lease.  Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements.  Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's audited financial results, capital expenditures and cash position for the year ended and as of December 31, 2012 being different from Verenium's estimated financial results, capital expenditures and cash position, the actual impact of Verenium's restatement of certain of its historical financial statements on its consolidated balance sheets and consolidated statement of operations for the relevant periods and its cash position being different from the estimated impact, Verenium's strategic focus, technologies, products and product candidates and product pipeline (including Verenium's ability to identify, develop and commercialize new products and product candidates, either independently or with collaborators or partners, and market demand for those products and product candidates), dependence on patents and proprietary rights,  protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements,  its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies, the timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture or partnership agreements and licenses on a timely basis or at all, and risks and other uncertainties more fully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's annual report on Form 10-K for the year ended December 31, 2012 and any updates contained in its subsequently filed quarterly reports on Form 10-Q .  These forward-looking statements speak only as of the date hereof, and Verenium expressly disclaims any intent or obligation to update these forward-looking statements.

Contact:

Sarah Carmody
Sr. Corporate Communications Manager
858-431-8581
sarah.carmody@verenium.com


'/>"/>
SOURCE Verenium Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Verenium Announces Appointment Of Brian Carter As Vice President Of Grain Processing
2. Verenium To Sponsor And Present At The 2013 Bio World Congress On Industrial Biotechnology
3. Verenium To Introduce New Enzyme Product At 2013 International Fuel Ethanol Workshop & Expo
4. Verenium To Present At Two Upcoming Conferences
5. Verenium Corporation to Announce First Quarter 2013 Financial Results
6. Verenium Reports Financial Results For The Fourth Quarter And Year Ended December 31, 2012
7. Verenium Announces Preliminary Financial Results For Fiscal 2012
8. Verenium To Present At The 25Th Annual Roth Conference
9. Verenium Appoints Holger Liepmann To Its Board Of Directors
10. Verenium To Sponsor The Renewable Fuels Association 18th Annual National Ethanol Conference
11. Novus International And Verenium Announce Important Progress In The Development Of Novel Enzymes For Animal Health & Nutrition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... In a list published by ... the state’s 76 fastest-growing private companies; a small percentage of the state's 615,000+ small ... on the percent change in revenue from 2012 to 2015. , As ...
(Date:5/3/2016)... ... May 03, 2016 , ... Kerafast Inc., developers of an ... across the globe, today announced the availability of a Zika virus antibody from ... treatment and prevention measures for the Zika virus, the virus’s geographical distribution continues ...
(Date:5/3/2016)... , May 3, 2016  Dr. Thomas P. ... in The Woodlands, Texas , now ... percent of treated fat cells in just 25-minutes, leaving ... to 90 percent of Americans report feeling bothered by ... fat reduction procedures are a growing industry. This innovative ...
(Date:5/2/2016)... 2016 Q BioMed Inc. (QBIO), ... Mannin Research Inc. will be attending the Association for ... from May 1-5, 2016 in Seattle Washington ... its vendors and research partners. The meeting provides organizations ... other collaborative opportunities for the MAN-01 program for treatment ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
(Date:3/18/2016)... , March 18, 2016 ... Suppliers of Biometrics, ICT, Manned & Unmanned Vehicles, Physical infrastructure ... & security companies in the border security market and the ... and Europe has led visiongain ... companies improved success. --> defence & security ...
Breaking Biology News(10 mins):